Amino Acid, Peptide, or Protein – Page 2

Ipsen to Acquire ImCheck Therapeutics for €350 Million to Expand Immunotherapy Pipeline

4 days ago talkbio0Tagged Acquisition, Anti-BTN3A Agonistic Monoclonal Antibody ICT01, BTN3A, butyrophilin superfamily, ImCheck Therapeutics, Immunotherapy, Ipsen, Leukemia, Myelocytic, Acute, Monoclonal Antibodies, Oncology Pipeline

Ipsen; ImCheck Therapeutics; acquisition; €350 million; €1 billion deal; immunotherapy; oncology pipeline; butyrophilin superfamily; ICT01; acute myeloid leukemia; monoclonal antibody; BTN3A

Inspira Technologies Appoints Former Johnson & Johnson Executive as VP of Global Sales

5 days ago talkbio0Tagged Appointments, Arginine Vasopressin-Neurophysin II Preproprotein, board of directors, commercialization, global sales, Health care facility, Inspira Technologies, Johnson & Johnson, Leadership, Mike Hershkovitz

Inspira Technologies; Mike Hershkovitz; Johnson & Johnson; VP of Global Sales; leadership appointment; healthcare; commercialization; board of directors

Companies Struggle to Accelerate Production of Bespoke mRNA Therapies

5 days ago talkbio0Tagged bespoke, Cancer Vaccines, cold chain logistics, Efficiency, innovation, Manufacturing, manufacturing challenges, mRNA production, mRNA therapies, Optimization, Precision Medicine, regulatory complexity, scalability

bespoke mRNA therapies; personalized medicine; manufacturing challenges; cancer vaccines; scalability; manufacturing efficiency; cold chain logistics; regulatory complexity; mRNA production innovation; AI optimization

Iambic’s AI-Designed HER2 Inhibitor IAM1363 Shows Early Anti-Tumor Activity in Heavily Pretreated Patients

5 days ago talkbio0Tagged AI-designed drug, brain-penetrant, Clinical Trials, IAM1363, Iambic Therapeutics, Malignant Neoplasms, Protein-tyrosine kinase inhibitor, Substance with human epidermal growth factor receptor 2 inhibitor mechanism of action (substance)

Iambic Therapeutics; AI-designed drug; IAM1363; HER2 inhibitor; cancer; clinical trial; Phase 1/1b; ESMO 2025; brain-penetrant; tyrosine kinase inhibitor

CatalYm Presents Long-Term Phase 1/2a Data for Visugromab at ESMO 2025

6 days ago talkbio0Tagged CatalYm, CPI-refractory tumors, ESMO, Growth Differentiation Factor 15, Visugromab

CatalYm; Visugromab; ESMO 2025; CPI-Refractory Tumors; GDF-15

Weight-loss drug stocks drop after Trump pledges major price cuts

6 days ago talkbio0Tagged Administration occupational activities, Drops - Drug Form, drug price, eli lilly, Glucagon-Like Peptide 1, Nordisk, Ozempic, Wegovy, Weight-Loss Agents

weight-loss drugs; ozempic; wegovy; novo nordisk; eli lilly; stock drop; drug pricing; trump administration; GLP-1

Tecentriq Demonstrates Survival Benefit in ctDNA-Guided Bladder Cancer Treatment at ESMO 2025

6 days ago talkbio0Tagged adjuvant treatment, atezolizumab, ctDNA-guided therapy, Disease-Free Survival, ESMO, genentech, IMvigor011, Malignant neoplasm of urinary bladder, muscle-invasive bladder cancer, Overall Survival, Roche (company), Signatera, Tecentriq

Tecentriq; atezolizumab; ctDNA-guided therapy; IMvigor011; bladder cancer; muscle-invasive bladder cancer; adjuvant treatment; overall survival; disease-free survival; ESMO 2025; Signatera; Genentech; Roche

FDA Approves Roche’s Biogen-Partnered Gazyva for Lupus Nephritis

6 days ago talkbio0Tagged Biogen, Gazyva, Lupus Nephritis, obinutuzumab, Roche (company), treatment approval, United States Food and Drug Administration

Gazyva; obinutuzumab; Roche; Biogen; FDA; lupus nephritis; treatment approval

SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented at ESMO 2025

7 days ago talkbio0Tagged Antibody-Drug Conjugates, BL-B01D1 - 303, Epidermal Growth Factor Receptor, iza-bren, Nasopharyngeal carcinoma, ORR, Phase 3 Clinical Trials, SystImmune

SystImmune; iza-bren; BL-B01D1-303; Phase III trial; nasopharyngeal carcinoma; dual primary endpoints; ORR; antibody-drug conjugate (ADC); EGFR×HER3 bispecific; ESMO 2025

Roche Inks $80M Upfront Deal for Hansoh’s Cancer ADC HS-20110

1 week ago talkbio0Tagged CDH17 protein, human, Colorectal Carcinoma, Hansoh Pharmaceutical, HS-20110, milestone payments, Roche (company), royalties, Solid Neoplasm, therapeutic autologous dendritic cells, upfront payment

Roche; Hansoh Pharmaceutical; ADC; HS-20110; CDH17; colorectal cancer; solid tumors; licensing deal; upfront payment; milestone payments; royalties